Matthew H. Kulke

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

(2023)10.1158/1078-0432.c.6530721.v1

Top 100%

0DataRank

Top 100%0 citations

Yvonne Y. Li, Liam F. Spurr, Atul B. Shinagare, Ritika Abhyankar, Emma C. Reilly +25 more

Papers

Driven by 12 papers — median percentile 0. Top paper: “Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)”.

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

Journal of Clinical Oncology(2022)10.1200/jco.22.01013

N/A

4.9DataRank · unranked

297 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +14 more

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

New England Journal of Medicine(2024)10.1056/nejmoa2403991

N/A

3.0DataRank · unranked

141 citations

Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher +19 more

Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma

Cancer Epidemiology Biomarkers & Prevention(2020)10.1158/1055-9965.epi-19-1315

N/A

0.802DataRank · unranked

15 citations

Annacarolina da Silva, Vicente Morales‐Oyarvide, Andressa Dias Costa, Margaret M. Kozak, Richard F. Dunne +23 more

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4073

N/A

0.538DataRank · unranked

35 citations

Yvonne Y. Li, Liam F. Spurr, Atul B. Shinagare, Ritika Abhyankar, Emma Reilly +25 more

Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors

Science Advances(2023)10.1126/sciadv.add9668

N/A

0.533DataRank · unranked

34 citations

Todd W. Dowrey, Carlos Villacorta Martin, Kevin Bi, Breanna Titchen, Shreya Johri +30 more

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

Annals of Oncology(2023)10.1016/j.annonc.2023.10.047

N/A

0.500DataRank · unranked

27 citations

Susan M. Geyer, F-S. Ou, Michael V. Knopp, Spencer C. Behr, Tyler Zemla +14 more

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4004

N/A

0.464DataRank · unranked

21 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +15 more

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad096

N/A

0.373DataRank · unranked

11 citations

Thomas A. Hope, Emily B Bergsland, Lisa Bodei, David Bushnell, Jennifer A. Chan +63 more

Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trials

Cancer(2021)10.1002/cncr.33540

N/A

0.373DataRank · unranked

11 citations

Carlo Carnaghi, Roberto Buzzoni, Juan W. Valle, Fabian Herbst, Antonia Ridolfi +5 more

Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.11.08.515538

N/A

0.243DataRank · unranked

3 citations

Todd W. Dowrey, Carlos Villacorta Martin, Kevin Bi, Breanna Titchen, Shreya Johri +27 more

Validation of a Crisis Standards of Care Model for Prioritization of Limited Resources During the Coronavirus Disease 2019 Crisis in an Urban, Safety-Net, Academic Medical Center*

Critical Care Medicine(2021)10.1097/ccm.0000000000005155

N/A

0DataRank · unranked